Elevance Health, Inc. (ELV)
Elevance Health, Inc. (ELV) is currently trading at $377.49, exhibiting technical weakness with an oversold RSI and price below key moving averages. Despite this, the company operates within the stable Healthcare Plans industry, a sector known for its resilience. Its market capitalization stands at a substantial $81.63 billion, indicating significant scale and market presence. While revenue growth has moderated to 1.4%, the company's earnings per share of $22.60 and a P/E ratio of 16.65 suggest a valuation that is not excessively stretched relative to its earnings power, though it lags behind some sector peers.
The company's financial health appears solid, supported by its position in a critical sector. However, the recent insider activity indicates a net selling pressure, with $8.1M in total purchases versus $169.7M in total sales, signaling a moderate insider selling. This, combined with the below-average revenue growth, warrants a cautious approach despite the oversold technical conditions that might suggest a near-term bounce potential. Investors should monitor for signs of accelerating growth or a shift in insider sentiment.
Price Analysis
Market Metrics
Peer Benchmarking
Valuation vs Sector (Healthcare)
Performance vs XLV
Sector Position Analysis
ELV Analysis
Elevance Health's technicals are currently bearish, with the price trading below its 20-day EMA ($388.02) and 50-day SMA ($396.65). The Relative Strength Index (RSI) is significantly oversold at 28.57, suggesting a potential for a short-term bounce. The MACD indicator is also negative at -5.97, reinforcing the current downtrend. The price is trading above its 200-day SMA ($351.15), which may act as a longer-term support level.
Key resistance levels to watch include the 20-day EMA and the 50-day SMA. A sustained break above these levels, coupled with improving RSI and MACD, would signal a potential trend reversal. Conversely, a failure to hold the 200-day SMA could lead to further downside. Volume analysis would be crucial to confirm any potential reversal or continuation of the current trend.
- Monitor Elevance Health's upcoming earnings reports closely for any signs of accelerating revenue growth or improved forward guidance, which could serve as a catalyst for a technical rebound.
- Given the oversold RSI, consider waiting for confirmation of a bullish reversal pattern or a break above key resistance levels before initiating new positions.
- The net selling by insiders warrants caution; ensure any investment aligns with a long-term strategy and consider the potential for continued pressure if selling persists.
The RSI is at 28.57, indicating the stock is in oversold territory, which historically can precede a short-term price bounce.
Source: Technical AnalysisRevenue growth has slowed to 1.4%, significantly below the sector average, posing a risk to future earnings expansion and valuation multiples.
Source: Fundamental DataInsiders have sold $5.3M versus purchased $5.1M, signaling a moderate insider selling and potentially indicating a lack of confidence in near-term stock performance.
Source: Insider ActivityThe median analyst target price of $405.00 suggests potential upside of 7.29% from the current price, indicating Wall Street optimism.
Source: Wall Street SummaryThe base case scenario for Elevance Health over the next 6-12 months suggests a period of consolidation or a slow recovery, driven by its defensive sector positioning and oversold technicals. A potential price target could be around the $405.00 analyst median target, representing a modest upside from current levels. This assumes a stabilization in revenue growth and a gradual improvement in market sentiment towards healthcare stocks.
However, downside risks remain significant. A failure to show signs of accelerating revenue growth or continued insider selling could push the stock lower, potentially testing the $351.15 200-day SMA. Upside catalysts would likely involve better-than-expected earnings reports, positive industry tailwinds, or a clear strategic initiative to boost growth, which could propel the stock towards its fair value estimate of $390.50.
Key Statistics
| Market Cap | 81.63B |
| P/E Ratio | 16.65 |
| EPS (TTM) | 22.60 |
| Dividend Yield | 1.81% |
| 52 Week High | 436.24 |
| 52 Week Low | 273.71 |
Elevance Health's valuation appears reasonable with a P/E ratio of 16.65, which is below the sector average of 22.50. This suggests that the market is not overly optimistic about its future earnings growth compared to its peers. The EPS of $22.60 provides a solid earnings base, but the modest revenue growth of 1.4% indicates challenges in expanding its top line.
The company's balance sheet strength and profitability metrics are not explicitly detailed in the provided data, but its consistent EPS suggests operational stability. The dividend yield of 1.81% offers a modest income stream. However, the decelerating revenue growth and net selling insider activity temper the fundamental outlook, suggesting that while the valuation is not stretched, significant near-term catalysts for fundamental improvement may be lacking.
Earnings & Growth Analysis
Specific recent earnings performance data (EPS beat/miss) is not provided. However, the reported EPS of $22.60 and a P/E ratio of 16.65 indicate a stable earnings profile. The revenue growth of 1.4% suggests a mature business with limited expansionary momentum in the near term. Forward guidance and specific revenue/EPS estimates are not available in the provided data, making it difficult to assess future earnings trajectory beyond the current stable performance.
Key Risks
The primary risks for Elevance Health include decelerating revenue growth, which may limit future earnings expansion. The current oversold technical conditions, while potentially leading to a bounce, also reflect underlying selling pressure. Furthermore, the net selling activity among insiders suggests a lack of strong conviction from management regarding near-term price appreciation.
Technical Indicators
| RSI (14) | 28.57 |
| MACD | -5.97 |
| SMA 50 | 396.65 |
| SMA 200 | 351.15 |
Market Correlations
How this stock moves relative to other assets
Based on 1 year of daily price data. Correlations may vary over different time periods.
Actionable Trade Plans
Specific entry, exit, and risk management levels
Entry Strategies (click to switch)
Risk Management
Profit Targets (Based on Conservative Entry)
Growth of $10,000
Compare with Another Ticker
Monte Carlo Projection (10yr)
People Also Watch
Compare ELV
Insider Trading Analysis
Source: SEC Form 4| Date | Insider | Type | Shares | Value |
|---|